Citi Appointed as Depositary Bank for Bicycle Therapeutics’ ADR Programme
LONDON–(BUSINESS WIRE)–Citi, acting through Citibank N.A., has been appointed by Bicycle
Therapeutics plc, a biotechnology company pioneering a new class of
therapeutics, to act as depositary bank for its American Depositary
Receipt (“ADR”) programme.
Bicycle Therapeutics’ ADRs trade on the Nasdaq Global Select Market
under the symbol “BCYC.” Each ADR represents one ordinary share of the
company.
Commenting on the appointment, Dirk Jones, Global Head of Issuer
Services, at Citi said:. “We look forward to supporting Bicycle
Therapeutics’ ADR programme and further expand the company’s investor
outreach through the expertise of our leading Investor Relations
Advisory team and the breadth of our global equity distribution network.”
For more information on Citi’s Depositary Receipt Services, visit www.citi.com/dr.
About Citi
Citi, the leading global bank, has approximately 200 million customer
accounts and does business in more than 160 countries and jurisdictions.
Citi provides consumers, corporations, governments and institutions with
a broad range of financial products and services, including consumer
banking and credit, corporate and investment banking, securities
brokerage, transaction services, and wealth management.
Additional information may be found at www.citigroup.com
| Twitter: @Citi | YouTube: www.youtube.com/citi
| Blog: http://blog.citigroup.com
| Facebook: www.facebook.com/citi
| LinkedIn: www.linkedin.com/company/citi
Contacts
Citi Media Contacts:
Capucine Boncenne
+44 (0) 20 7508
9355
capucine.boncenne@citi.com